Evotec SE booked revenue of €133.1 million in the first quarter, up by 11% from a year earlier, as its service offering to pharma and biotech companies continued to expand both in quantity and scope. Concurrent with this expansion, spending on both R&D and administration rose by 23% in the quarter. This, plus the winding down of payments from Sanofi SA relating to a multi-year collaboration, left operating profit at €6.8 million, down from €16.1 million a year earlier.
